Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

726 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase 2/3 study of S-217622 in participants with SARS-CoV-2 infection (Phase 3 part).
Yotsuyanagi H, Ohmagari N, Doi Y, Imamura T, Sonoyama T, Ichihashi G, Sanaki T, Tsuge Y, Uehara T, Mukae H. Yotsuyanagi H, et al. Among authors: mukae h. Medicine (Baltimore). 2023 Feb 22;102(8):e33024. doi: 10.1097/MD.0000000000033024. Medicine (Baltimore). 2023. PMID: 36827007 Free PMC article. Clinical Trial.
Efficacy and safety of nelfinavir in asymptomatic and mild COVID-19 patients: a structured summary of a study protocol for a multicenter, randomized controlled trial.
Hosogaya N, Miyazaki T, Fukushige Y, Takemori S, Morimoto S, Yamamoto H, Hori M, Kurokawa T, Kawasaki Y, Hanawa M, Fujii Y, Hanaoka H, Iwami S, Watashi K, Yamagoe S, Miyazaki Y, Wakita T, Izumikawa K, Yanagihara K, Mukae H, Kohno S; Nelfinavir Study Group. Hosogaya N, et al. Among authors: mukae h. Trials. 2021 Apr 28;22(1):309. doi: 10.1186/s13063-021-05282-w. Trials. 2021. PMID: 33910617 Free PMC article.
Detection of SARS-CoV-2 using qRT-PCR in saliva obtained from asymptomatic or mild COVID-19 patients, comparative analysis with matched nasopharyngeal samples.
Ota K, Yanagihara K, Sasaki D, Kaku N, Uno N, Sakamoto K, Kosai K, Miyazaki T, Hasegawa H, Fujita A, Tashiro M, Tanaka T, Izumikawa K, Ariyoshi K, Mukae H, Yasuda J, Morita K, Kohno S. Ota K, et al. Among authors: mukae h. PLoS One. 2021 Jun 10;16(6):e0252964. doi: 10.1371/journal.pone.0252964. eCollection 2021. PLoS One. 2021. PMID: 34111203 Free PMC article.
Discrepancy of SARS-CoV-2 PCR results due to the sample collection sites and possible improper sampling.
Irifune S, Ashizawa N, Takazono T, Mutantu P, Nabeshima T, Ngwe Tun MM, Ota K, Hirayama T, Fujita A, Tashiro M, Tanaka T, Yamamoto K, Imamura Y, Miyazaki T, Sawai T, Izumikawa K, Yanagihara K, Morita K, Mukae H. Irifune S, et al. Among authors: mukae h. J Infect Chemother. 2021 Oct;27(10):1525-1528. doi: 10.1016/j.jiac.2021.07.008. Epub 2021 Jul 16. J Infect Chemother. 2021. PMID: 34294531 Free PMC article.
Phase II Clinical Trial of Combination Therapy with Favipiravir and Methylprednisolone for COVID-19 with Non-Critical Respiratory Failure.
Shindo Y, Kondoh Y, Kada A, Doi Y, Tomii K, Mukae H, Murata N, Imai R, Okamoto M, Yamano Y, Miyazaki Y, Shinoda M, Aso H, Izumi S, Ishii H, Ito R, Saito AM, Saito TI, Hasegawa Y. Shindo Y, et al. Among authors: mukae h. Infect Dis Ther. 2021 Dec;10(4):2353-2369. doi: 10.1007/s40121-021-00512-9. Epub 2021 Aug 8. Infect Dis Ther. 2021. PMID: 34368914 Free PMC article.
Performance of anti-SARS-CoV-2 antibody testing in asymptomatic or mild COVID-19 patients: A retrospective study in outbreak on a cruise ship.
Kaku N, Nishimura F, Shigeishi Y, Tachiki R, Sakai H, Sasaki D, Ota K, Sakamoto K, Kosai K, Hasegawa H, Izumikawa K, Ariyoshi K, Mukae H, Yasuda J, Morita K, Kohno S, Yanagihara K. Kaku N, et al. Among authors: mukae h. PLoS One. 2021 Sep 28;16(9):e0257452. doi: 10.1371/journal.pone.0257452. eCollection 2021. PLoS One. 2021. PMID: 34582459 Free PMC article.
A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part.
Mukae H, Yotsuyanagi H, Ohmagari N, Doi Y, Imamura T, Sonoyama T, Fukuhara T, Ichihashi G, Sanaki T, Baba K, Takeda Y, Tsuge Y, Uehara T. Mukae H, et al. Antimicrob Agents Chemother. 2022 Oct 18;66(10):e0069722. doi: 10.1128/aac.00697-22. Epub 2022 Sep 13. Antimicrob Agents Chemother. 2022. PMID: 36098519 Free PMC article. Clinical Trial.
A Multicenter Randomized Controlled Trial To Evaluate the Efficacy and Safety of Nelfinavir in Patients with Mild COVID-19.
Miyazaki T, Hosogaya N, Fukushige Y, Takemori S, Morimoto S, Yamamoto H, Hori M, Ozawa Y, Shiko Y, Inaba Y, Kurokawa T, Hanaoka H, Iwanami S, Kim K, Iwami S, Watashi K, Miyazawa K, Umeyama T, Yamagoe S, Miyazaki Y, Wakita T, Sumiyoshi M, Hirayama T, Izumikawa K, Yanagihara K, Mukae H, Kawasuji H, Yamamoto Y, Tarumoto N, Ishii H, Ohno H, Yatera K, Kakeya H, Kichikawa Y, Kato Y, Matsumoto T, Saito M, Yotsuyanagi H, Kohno S. Miyazaki T, et al. Among authors: mukae h. Microbiol Spectr. 2023 Jun 15;11(3):e0431122. doi: 10.1128/spectrum.04311-22. Epub 2023 May 4. Microbiol Spectr. 2023. PMID: 37140398 Free PMC article. Clinical Trial.
Safety and efficacy of 5-aminolevulinic acid phosphate/iron in mild-to-moderate coronavirus disease 2019: A randomized exploratory phase II trial.
Tanaka T, Tashiro M, Ota K, Fujita A, Sawai T, Kadota J, Fukuda Y, Sumiyoshi M, Ide S, Tachikawa N, Fujii H, Hibino M, Shiomi H, Izumida M, Matsui K, Yamauchi M, Takahashi K, Yamanashi H, Sugimoto T, Akabame S, Umeda M, Shimizu M, Hosogaya N, Kosai K, Takeda K, Iwanaga N, Ashizawa N, Hirayama T, Takazono T, Yamamoto K, Imamura Y, Miyazaki T, Kobayashi Y, Ariyoshi K, Mukae H, Yanagihara K, Kita K, Izumikawa K. Tanaka T, et al. Among authors: mukae h. Medicine (Baltimore). 2023 Aug 25;102(34):e34858. doi: 10.1097/MD.0000000000034858. Medicine (Baltimore). 2023. PMID: 37653769 Free PMC article. Clinical Trial.
726 results